A Phase 1 Study of MORAb-003 in Patients With Solid Tumor
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To investigate dose-limiting toxicity and estimate maximum tolerated dose.
7 weeks
Yes
Chifumi Kitamura
Study Director
JAC PCU Eisai Co., Ltd.
Japan: Ministry of Health, Labor and Welfare
MORAB-003-J081-102
NCT01049061
January 2010
December 2012
Name | Location |
---|